Subscribe
Models
HUGO Series 🌟
Cell Line Models
Services
Preclinical Efficacy
Resources
About Us
B6-hBAFFR (hTNFRSF13C) Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
B6-hBAFFR (hTNFRSF13C) Mouse
Product Name
B6-hBAFFR (hTNFRSF13C) Mouse
Product ID
C001711
Strain Name
C57BL/6NCya-Tnfrsf13ctm1(hTNFRSF13C)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-hBAFFR (hTNFRSF13C) Mouse (Catalog C001711) were purchased from Cyagen.”
HUGO-GT Humanized ModelsImmune Target Humanized Mouse ModelsCytokine Gene Humanized Mouse Models
Systemic Lupus Erythematosus
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
HUGO-GT Humanized ModelsImmune Target Humanized Mouse ModelsCytokine Gene Humanized Mouse Models
Systemic Lupus Erythematosus
Basic Information
Related Resource
Basic Information
Gene Name
TNFRSF13C
Gene Alias
BAFFR, CD268, CVID4, BAFF-R, BROMIX, prolixin
NCBI ID
Chromosome
Chr 22 (Human)
MGI ID
Datasheet
Strain Description
The gene TNFRSF13C encodes the B cell-activating factor receptor (BAFF-R), also known as BLyS receptor 3 (BR3) or CD268. As a member of the tumor necrosis factor receptor superfamily (TNFRSF), BAFF-R functions as a crucial type III transmembrane signaling protein on lymphocytes. Its expression is predominantly observed on the surface of B cells throughout various stages of their development, from transitional to mature naive and memory populations, underscoring its vital role in peripheral B cell homeostasis [1]. BAFF-R serves as the primary receptor for the cytokine BAFF (TNFSF13B), and their interaction delivers essential survival and maturation signals to B cells, mediated through downstream pathways including the activation of NF-κB and PI3K. Genetic alterations in TNFRSF13C, including point mutations and deletions, or dysregulation of the BAFF-BAFF-R axis, are increasingly recognized for their contribution to immune pathology [2]. Such aberrations are associated with primary immunodeficiencies like common variable immunodeficiency (CVID), characterized by profound defects in antibody production and recurrent infections, as well as a range of autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjögren's syndrome, and certain B cell malignancies [2-3]. The critical, non-redundant function of BAFF-R in B cell biology highlights its significance as a key node in adaptive immunity and positions the BAFF-BAFF-R pathway as a compelling target for therapeutic intervention in a spectrum of immune-mediated disorders.
The B6-hBAFFR (hTNFRSF13C) mouse is a humanized model constructed by replacing the sequence of the mouse Tnfrsf13c endogenous extracellular domain in situ with the corresponding extracellular domain from the human TNFRSF13C. The B6-hBAFFR (hTNFRSF13C) mice can be used for the study of the pathogenesis of immune-mediated disorders such as common variable immunodeficiency (CVID), systemic lupus erythematosus (SLE), and Sjögren's syndrome, and certain B cell malignancies, as well as for TNFRSF13C-targeted drug development.
Reference
Schweighoffer E, Tybulewicz VL. BAFF signaling in health and disease. Curr Opin Immunol. 2021 Aug;71:124-131.
Sevdali E, Block Saldana V, Speletas M, Eibel H. BAFF receptor polymorphisms and deficiency in humans. Curr Opin Immunol. 2021 Aug;71:103-110.
Tagami N, Yuda J, Goto Y. Current status of BAFF targeting immunotherapy in B-cell neoplasm. Int J Clin Oncol. 2024 Nov;29(11):1676-1683.
Strain Strategy
The mouse Tnfrsf13c endogenous extracellular domain was replaced with the human TNFRSF13C extracellular domain.

Figure 1. Gene editing strategy of B6-hBAFFR (hTNFRSF13C) Mice.
Application Area
TNFRSF13C-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of immune-mediated disorders such as common variable immunodeficiency (CVID), systemic lupus erythematosus (SLE), and Sjögren's syndrome;
Research on the pathological mechanisms and therapeutic approaches of certain B cell malignancies.
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

